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Abstract
Background: There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our
objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care
programme in Southern Africa.
Methods/Findings: We analysed the direct costs of treating HIV-infected adults enrolled in the managed care programme
from 3 years before starting non-nucleoside reverse transcriptase inhibitor-based ART up to 5 years afterwards. The CD4 cell
count criterion for starting ART was ,350 cells/ml. We explored associations between variables and mean total costs over
time using a generalised linear model with a log-link function and a gamma distribution. Our cohort consisted of 10,735
patients (59.4% women) with 594,497 mo of follow up data (50.9% of months on ART). Median baseline CD4+ cell count and
viral load were 125 cells/ml and 5.16 log10 copies/ml respectively. There was a peak in costs in the period around ART
initiation (from 4 mo before until 4 mo after starting ART) driven largely by hospitalisation, following which costs plateaued
for 5 years. The variables associated with changes in mean total costs varied with time. Key early associations with higher
costs were low baseline CD4+ cell count, high baseline HIV viral load, and shorter duration in HIV care prior to starting ART;
whilst later associations with higher costs were lower ART adherence, switching to protease inhibitor-based ART, and
starting ART at an older age.
Conclusions: Drivers of mean total costs changed considerably over time. Starting ART at higher CD4 counts or longer pre-
ART care should reduce early costs. Monitoring ART adherence and interventions to improve it should reduce later costs.
Cost models of ART should take into account these time-dependent cost drivers, and include costs before starting ART.
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Access to combination antiretroviral therapy (ART) is rapidly
expanding in resource-limited settings. Data on the costs of
providing HIV health care and how these change over time are
important for guiding resource allocation. However, there are few
good quality studies of the direct health care costs of HIV
infection, as illustrated by a recent systematic review that found
only nine studies from the ART era that fulfilled inclusion criteria
[1]. Data on costs prior to starting ART are limited as most cost
studies only report costs once ART has been commenced. A
recent South African study reported that health care costs were
almost twice as high in the first year on ART in comparison with
the second year [2]. However, the sample size was small, patients
had advanced disease, follow up was relatively short, and the
period of higher costs in the first year on ART was not defined.
Delays in establishing public ART programmes in South Africa
until 2003 [3], together with studies highlighting the detrimental
effects of HIV in the workplace [4], resulted in the scaling up of
access to ART through private medical insurance funds from as
early as 1998 [5]. Given the level of need for improved access to
ARTinSouth Africa, whichhasthe world’s largest numberof HIV-
infected people [6], the government has identified partnerships with
the private sector as a key mechanism for enhancing access [7]. In
the private sector, starting ART is encouraged earlier than current
WHO guidelines for resource-limited settings [8], thus enabling
exploration of the cost implications of starting ART earlier.
The objective of this study was to explore health care costs in a
South African private sector HIV/AIDS programme, with a
special focus on the determinants of costs around the period of
ART initiation, as well as the determinants of costs during the later
phases of ART.
Methods
Ethics Statement
The study was approved by the Research Ethics Committee,
University of Cape Town and by the Board of Directors of Aid for
AIDS (AfA). Informed consent was not required as the data were
analyzed anonymously, but all patients signed consent for their
information to be entered into the AfA database.
Data Source
Data for this study were extracted from a database of patients
enrolled with AfA, a group that manages HIV-related care for a
number of medical insurance funds and companies in the private
sector in Southern Africa [9]. Registration of eligible patients with
AfA is done by the private doctor looking after the individual
patient (i.e., there are no clinics, but some private doctors run
exclusive HIV practices). Demographic data, CD4+ cell count,
viral load, and previous ART history is captured centrally. Patients
are managed according to a clinical guideline and any decision to
start ART, change ART regimen, and treat certain opportunistic
infections is subject to review and approval by AfA clinical staff.
The antiretroviral guidelines are similar in many respects to WHO
guidelines for resource-poor settings [8] and the South African
public sector programmes, but ART is initiated earlier and there is
room for choice of individual antiretroviral drugs. For example
several ritonavir-boosted protease inhibitors (PIs) are available
rather than the single one available in the South African public
sector. ART can be initiated at CD4+ cell counts ,350 cells/ml
rather than ,200 cells/ml in the South African public sector, but
similar to WHO guidelines that recommend initiation with CD4+
cell counts ,350 cells/ml with symptomatic disease. The recom-
mended initial regimen is a combination of two nucleoside reverse
transcriptase inhibitors (NRTIs) and a non-nucleoside reverse
transcriptase inhibitor (NNRTI). Second line therapy consists of a
boosted PI with two NRTIs. CD4+ cell counts and viral loads are
monitored 6 monthly. There is a telephonic counselling service
provided by AfA, although counselling is not routine but done on
demand. Drugs are collected monthly from private pharmacies.
Inclusion Criteria
Two of the medical insurance funds contracted to AfA were
selected on the grounds that they had large numbers of patients,
similar treatment benefits, and required no co-payment for ART.
This selection allowed us to describe costs and drivers of costs
without relating to the patient’s ability to pay, which has been
reported to influence outcomes on ART [10–12]. Patients were
included in the study if they were ART naı ¨ve at entry (women who
had received prophylaxis for prevention of mother-to-child
transmission were not excluded); adult (19 y or older at the time
of approval for ART); and if ART was started between November
1998 and November 2007. Patients were excluded if they had
missing cost data over the entire period. To make our findings
more generalisable, we only included patients starting ART with
an NNRTI plus two NRTIs, as recommended by the WHO for
resource-limited settings [8].
Cost Data
Direct health care costs were analysed from the provider’s
perspective [13], and indirect costs were not assessed. Submitted
health care claims were captured into a central database. The tariff
amount (which is the amount agreed to annually following
negotiations between private healthcare providers and funders)
was used as a proxy for direct health care costs, as opposed to the
amount charged by the provider or the amount reimbursed to the
patient. Of the 49,517 unique claim categories in the AfA
database, 4,000 accounted for over 95% of total costs. These 4,000
claim categories were grouped into the following categories: ART,
other medication, maternity-related care (antenatal services,
delivery, caesarean section, and postdelivery paediatric care),
general practitioner care, specialist care, hospital accommodation
and procedures, CD4+ cell count and viral load monitoring, other
investigations (e.g., laboratory tests and radiology).
The prices of antiretroviral drugs have fallen dramatically over
the period of our study. To account for this decrease we deflated
ART prices to the April 2007 level. All other health care costs have
increased; these were inflated to the April 2007 level using the
consumer price index net of mortgage payments (CPIX) [14]. The
average South African rand to US$ exchange rate in April 2007
(R7.14 to US$1) was used to convert costs to US$ equivalents [15].
Exploratory Cost Analysis
The mean total cost and its components were explored from
36 mo before starting ART to 60 mo on ART. Costs were broken
down into the following components: ART, other medication,
hospitalisation, investigations, CD4+ cell count and HIV viral load
monitoring, general practitioner consultations, specialist consulta-
tions, maternity, and auxiliary care. This exploratory analysis
revealed a marked peak in cost from 4 mo before starting ART
until 4 mo on ART. This 8-mo interval is denoted the ‘‘peri-
ART’’ period in this study.
Statistical Methods
Even though health care costs are often right-skewed, with a
minority of patients incurring very high costs, the health
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best guided by analyses of arithmetic mean costs, as the mean
provides information on the costs of treating the entire population
[16]. Thus ordinary least squares (OLS) regression models and
generalised linear models (GLM) were considered [16,17]. The
month in which patients started ART was set as the zero month
for all patients, which provided a common reference point for all
the patients in our analysis. We divided the period from 4 mo
before to 60 mo after starting ART into 4-mo intervals and
determined the mean total cost in each interval. As many months
had zero costs (.10%), using the mean cost over 4 mo intervals
resulted in few zero values in the outcome variable, thus avoiding
the need for zero-inflated models. A GLM with a gamma
distribution and a log-link function was selected on grounds that
it could describe the distribution of the data. An OLS model was
abandoned because it was unable to adequately account for the
patients with very high costs, which was a significant proportion of
total costs. With a log-link function, the variables are associated
with a proportional change in total mean costs. Improved residual
diagnostics, lower Akaike Information Criteria (AIC), and
improved trend prediction were used in the model development
and refinement.
The time-varying associations between mean total cost and the
variables was modelled using three methods: a separate model for
each 4-mo time interval using categorical variables, and two
models with categorical or continuous variables over the entire
interval with time included as a variable, which also interacted
with the other variables. Effect estimates and their significance at
the 95% level were assessed using robust standard errors with
clustering at an individual level. Data storage, basic calculations,
and data extraction was handled in Microsoft Access 2003 [18]
and statistical analysis was performed in Stata 10 [19].
The following variables were considered in our analysis:
baseline CD4+ cell count and HIV viral load (baseline was
defined as the most recent result within 6 mo before starting
ART), ART adherence assessed by monthly pharmacy claims,
age, sex, the NNRTI and the NRTI combination used in patients
on first line therapy, whether the patient switched to PI-based
second line ART, and the duration of CD4+ cell count monitoring
(as a proxy for being in HIV care) prior to starting ART. Patients
with less than 4 mo of claims data after starting ART were
excluded on the grounds that we were unable to assess their ART
adherence over shorter time intervals. We split the continuous
variables into the following categories: (1) Baseline CD4+ cell
count was divided into four groups: 0–49, 50–199, 200–349, and
$350 cells/ml. (2) HIV viral load was categorised as
$100,000 copies/ml or ,100,000 copies/ml. (3) The mean
ART adherence was determined using pharmacy refill data and
divided into quartiles. (4) The NNRTI was included as a binary
variable (either efavirenz or nevirapine); whereas (5) the NRTI
combination in first line was divided into three groups: zidovudine
and lamivudine, stavudine and lamivudine, or any other
combination. (6) A binary variable was used to reflect whether
or not the patient was on second line ART. (7) Age was divided
into quartiles. (8) Sex was included as a binary variable. (9) Patient
follow-up for HIV prior to starting ART was measured by the
length of time between the first CD4+ cell count and the date of
starting ART, and was categorised as less than 6 mo and more
than 6 mo.
Results
10,735 patients met our eligibility criteria. The characteristics of
the cohort are described in Table 1. There were almost 600,000
patient months of observation, about half of which were on ART.
Median follow-up on ART was 26 mo. Baseline body mass index
(BMI) was only available for 4,416 of the patients: 13% were
,18.5 kg/m
2, 52% were $18.5 kg/m
2 and ,25 kg/m
2, and
35% were $25 kg/m
2. The most common first line and second
line antiretroviral regimens were zidovudine, lamivudine, and
efavirenz and lopinavir/ritonavir, zidovudine, and didanosine,
respectively. CD4 and viral load monitoring were done 1.5 times
per annum on average. Hospitalisation rates were 441 d per 100
patient years of observation (PYO) in the first 6 mo of ART and
179 d per 100 PYO subsequently. Hospitalisation incidence was
highest in patients in the lowest CD4 count stratum.
The proportion of patients who left the scheme was 31% overall
and 24% at 2 y. Patients who left the scheme either changed their
employment, switched to a different medical insurance scheme, or
voluntarily stopped their contributions to the insurance scheme.
Patients who left the scheme differed from those who did not leave in
the following baseline characteristics (established using the Wilcoxon
rank sum test for continuous variables and Chi-squared test for
categorical variables): viral load (median of 5.2 versus 5.1 log10,
p=0.0016), proportion female sex (57% versus 60%, p=0.0001), and
age (37.4 y versus 37.0 y, p=0.0006). Importantly, these baseline
differences are not clinically significant and the CD4+ cell count did
not differ significantly (median of 127 versus 123 cells/ml, p=0.137).
Exploratory Cost Analysis
The cost data were highly skewed with 10% of the population
accounting for 90% of the costs. Figure 1 shows the mean monthly
cost and its components. The mean monthly cost rose from a
plateau of around US$100 per month before ART, to a peak of
around US$500 in the peri-ART period, before dropping down to
a new higher plateau of around US$200 on ART. Median (IQR)
monthly costs are shown in Figure S1.
Multiple Regression Analysis
After excluding patients with missing demographic and baseline
viral load and CD4+ cell count data, 7,427 patients were included
in this analysis, and their characteristics are shown in Table 1. The
summary statistics for this subset were comparable with the full
dataset.
In our first analysis, we modelled each 4-mo time interval
separately. We found that lower baseline CD4+ cell counts and
high HIV viral loads were associated with increased mean total
cost predominantly from 4 mo before to 8 mo after starting ART.
In contrast, the highest ART adherence quartile was increasingly
associated with lower mean total cost over time when compared
with the lowest quartile (Figure 2A). When ART-related costs were
excluded (on the grounds that high adherence would result in
more ART-related costs), the association was more marked. In a
subanalysis, the effect of lagged ART adherence (adherence in the
prior 4 mo) on costs per 4-mo period was assessed. Again higher
adherence in the prior 4 mo was associated with lower costs
(Figure 2B). Being on second line (PI-based) ART was associated
with higher costs throughout the time period. The other variables
were associated with small effects (,10%), which were largely not
significant. In a subanalysis, we excluded maternity (which is
associated with high costs as nearly all women deliver by caesarean
section) and ART costs (a lower proportion of women started
efavirenz, which is teratogenic and more expensive than
nevirapine) and found the association between sex and mean total
cost was not consistent and marginal (,10%).
Mean total costs fell over the first 24 mo on ART and thereafter
cost remained constant. Similarly, the associations between many
variables and mean total costs changed over the first 24 mo and
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four periods (24 to 4 mo, 5–12 mo, 13–24 mo, and .24 mo)
described time-dependent association between time and total
mean cost and its interaction with the other variables. The results
from this multiple regression analysis are found in Table 2.
We found that costs were very high in the peri-ART period.
Mean monthly costs were more than 3 times higher in this period
and the association between costs and baseline CD4 count and
baseline viral load were more marked in the peri-ART than in
later time periods. In the above analysis, we excluded patients who
died within the first 4 mo on ART because we could only estimate
ART adherence over a period of 4 mo or longer. However given
that patients who died might incur significant costs, we performed
an additional subanalysis including these early deaths. This subset
included 8,559 patients. The findings were similar but the
associations between variables and total mean costs diminished
marginally when we repeated the multiple regression analysis with
the ART adherence variable excluded (unpublished data).
Finally, we explored continuous models for ART adherence,
age at starting ART, baseline viral load, and baseline CD4+ cell
count (only counts ,350 cells/ml were analysed as patients with
higher counts were started on ART for serious HIV-related
morbidity): polynomial functions of the 2nd degree were used for
all the variables except ART adherence (4th degree polynomial)
and baseline HIV viral load (3rd degree polynomial) were used.
We felt that the duration of CD4+ cell count monitoring before
staring ART was better handled as a categorical variable. Time
and its interactions with the other variables displayed nonlinear
associations with total mean cost for the first 24 mo; thereafter
trend was approximately linear. A restricted cubic spline (a cubic
spline with linear tails) with three knots placed 24t o21 mo, 4–
7 mo, and 16–19 mo fitted the observed trends in our data; we
experimented with the placement and number of knots using the
Akaike Information Criteria and predictive plots to guide the final
model selection. An interaction with the spline function for time
was used for all variables except ART (first line versus second line)
as the trend over time was difficult to quantify. Overall, the model
was able to describe the trends in the data well, though in some
intervals the trends in the baseline viral load and age variables
were not well approximated at the extremes. While the main
findings from this analysis using continuous variables did not differ
from the previous analysis using categorical variables, some
subtleties not previously shown were found in the relationships
between costs and baseline CD4+ cell count and ART adherence.
The association between baseline CD4+ cell count and mean
total costs over time is shown in Figure 3; costs within each
interval were compared with a referent group (CD4+ cell
count=200 cells/ml). Initially, the association with mean total
cost followed a j-shape, with low CD4 counts associated with very
high costs but also a modest increase in costs in patients with high
counts. Over time the association between CD4+ cell count and
mean total costs became less marked but costs were lowest for
patients with higher CD4 counts. The association between ART
adherence and mean total costs is shown in Figure 4; costs within
Table 1. The characteristics of the cohort.
Characteristics Overall n=10,735 Regression Subset n=7,427
Patient months included in analysis Overall 594,497 282,141
On ART 302,579 (50.9%) 252,433
Duration on ART (mo) Median 26 33
IQR (9–44) (16–50)
Age at starting ART (y) Median 37 37
IQR (32–43) (32–43)
Sex Female 6,379 (59.%) 4,557 (61%)
Male 4,356 (41%) 2,897 (39%)
Patient status at end of study period Active 6,339 (59%) 4,217 (56%)
Left scheme 3,329 (31%) 2,669 (36%)
Dead 1,067 (10%) 1,067 (8%)
Baseline CD4+ cell count Median 125 cells/ml 125 cells/ml
IQR (49–203) (55–204)
Missing 1,726 N/A
Baseline viral load (log10) Median 5.20 5.16
IQR (4.70–5.60) (4.66–5.59)
Missing 2,031 N/A
NNRTI used in first line Nevirapine 2,655 (28%) 2,432 (28%)
Efavirenz 6,711 (72%) 6,127 (72%)
NRTI combination in first line AZT+3TC 6,950 (65%) 4,945 (67%)
D4T+3TC 1,564 (15%) 1,684 (23%)
Other 2,221 (20%) 798 (10%)
Duration of CD4+ cell count monitoring before starting ART (mo) Median 1.5 1.5
IQR (0.7–4.2) (0.7–4.2)
3TC, lamivudine; AZT, zidovudine; D4T, stavudine; IQR, interquartile range; N/A, not applicable.
doi:10.1371/journal.pmed.1000189.t001
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adherence 75%). Initially, the model found three peaks: one
around highly adherent patients, another around 50% adherence,
and a smaller peak at very low adherence. Over time the lower
peak fell away, the middle dominant peak moved to be centred at
around 30% adherence, while the highly adherent patients were
now associated with the lowest costs. Very low ART adherence
was associated with low costs in all time intervals except in the
peri-ART period. The association between mean total cost and
baseline viral load (Figure S2) age at starting ART (Figure S3) are
found in the supporting information (Figures S1–S3).
Discussion
We analysed the direct health care costs of treating over 10,000
HIV-infected adults enrolled in a Southern African managed care
ART programme with almost 600,000 patient months of follow-
up, spanning 3 y before ART to 5 y on ART. We found a peak in
costs in the period around the time of ART initiation, thereafter
total mean costs dropped off to a plateau that persisted for 5 y. An
important and novel feature of our study was the presentation of
time-dependent associations between total mean costs and relevant
variables. We identified lower baseline CD4+ cell count, higher
baseline viral load, and shorter duration of CD4+ cell count
monitoring before starting ART (as a proxy for HIV care) as being
independently associated with higher costs in the early time
periods. Lower ART adherence, being on second line ART, and
starting ART at an younger age were most strongly associated with
lower mean costs in later time periods, and the association with
ART adherence became more marked over time.
The peak in costs in the peri-ART period we observed was
largely driven by the high proportion of patients requiring
hospitalisation. High rates of early morbidity, often resulting in
hospitalisation or death, are characteristic of antiretroviral
programmes in resource-limited settings. Patients on ART in
low-income countries have higher early mortality compared with
high-income countries, even after correcting for baseline differ-
ences in CD4+ cell counts [20]. A strength of our study is the
analysis of cost data before starting ART. Few ART cost analyses
include the period before starting ART. Higher costs in the first
year on ART compared with later years with high rates of
hospitalisation was reported in another South African study of a
public sector ART programme, but they only assessed costs for
1 mo before starting ART and did not attempt to more accurately
define the period of high cost [2]. Given our finding of high costs
in the 4-mo period before starting ART, which was equivalent to
1.5 y of cost in patients on ART after the first year, other studies
might have significantly underestimated the costs of providing
HIV care just prior to starting ART.
We found that higher ART adherence was associated with lower
costs particularly after removing antiretroviral drug costs. The
magnitude of this association becomes greater as duration on ART
increases. However, the continuous model showed that while highly
adherent patients (.92%) were associated with the lowest total
mean costs in later time intervals, they were associated with higher
costs in the early time intervals.A similar association was found with
high baseline CD4+ cell counts (.300 cells/ml) being associated
with higher costs initially. These findings could be attributed to
increased health-seeking behaviour leading to increased costs
initially, but reduced costs over time. Very low ART adherence
was associated with low total mean costs in all time intervals as these
patients are presumably accessing minimal services. Our group has
previously reported that ART adherence assessed by pharmacy
refills in this cohort predicted both virological suppression [21] and
survival [22]. Poor adherence limits the effectiveness of ART, drives
resistanceto first line regimens, and thusleads to earlier switchingto
costly second line ART. Despite the important role of ART
adherence, existing economic models fail to include it.
Figure 1. Mean categorised total monthly costs from 36 mo before starting to 60 mo on ART.
doi:10.1371/journal.pmed.1000189.g001
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PLoS Medicine | www.plosmedicine.org 5 December 2009 | Volume 6 | Issue 12 | e1000189Figure 2. The proportional change in mean total costs associated with ART adherence with 95% confidence intervals. (A) The highest
overall ART adherence quartile was compared with the lowest adherence quartile within each time interval (ART costs included and excluded) from
4 mo before starting ART to 60 mo on ART. (B) The highest lagged ART adherence group was compared with the lowest group ($3 monthly versus
#1 monthly refills in the previous 4-mo period) within each time interval from 4 mo before starting ART to 60 mo on ART.
doi:10.1371/journal.pmed.1000189.g002
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costs has several important public health implications. The high
early costs of ART programmes could be reduced by starting
ART at a CD4+ cell count of ,350 cells/mlr a t h e rt h a n
,200 cells/ml (for patients without major symptomatic HIV
disease). Our cohort does not allow for an evaluation of starting
ART in patients with baseline CD4+ cell counts $350 cells/ml
because AfA guidelines only allow these patients to start ART
following an AIDS-defining illness or with other serious co-
morbidity: costs were actually higher in this group compared
with those starting ART with baseline CD4+ cell counts 200–
349 cells/ml, presumably reflecting the costs of treating the
morbidity that was the criterion for starting ART. The second
intervention that could reduce early costs would be the earlier
identification of HIV infection, illustrated by our finding that
being in HIV care for more than 6 mo prior to starting ART
reduced costs in the peri-ART period. The key driver of later
costs with public health implications is ART adherence. Higher
adherence prolongs time on the cheaper first line regimen, but
also reduces non-ART direct costs in our study. The third
intervention that might reduce costs would be to encourage ART
programmes to invest in systems to monitor ART adherence and
implement effective interventions if adherence is suboptimal.
ART adherence could be monitored over short time periods of 3
to 4 mo, which identifies patients incurring higher costs and
those at risk of virological failure [23].
We estimate that annual total direct health care costs are
approximately US$2,400 (after the peak in costs in the peri-ART
period) for patients accessing ART in the private sector. Lower
costs were reported in two other South African studies. Harling
reported costs of $2,502 in year one and $1,372 in year two of a
donor-funded public sector program [24]. Rosen estimated the
ART component of care to be US$757–US$1,126 in the first year
of several different models of ART delivery to public sector
patients, but non-ART–related clinic visits and hospitalisations
were not included [25]. The incidence rate of hospitalisation we
found in the first 6 mo on ART was similar to that reported in a
South African public sector ART programme in the first 48 wk on
ART, but our incidence was higher in later periods, which would
increase costs [24]. Higher rates of hospitalisation in the private
sector compared with the public sector after the initial period of
ART probably reflect greater access in the private sector. Other
factors driving higher costs in the private sector compared with
public sector are higher costs for hospitalisation (US$340 versus
US$202 per day, respectively) and viral load tests (US$62 versus
US$42, respectively) [26].
Table 2. The proportional change in mean total cost modelled using a multiple generalised linear model regression.
Variable Time Intervals (mo)
24 to 4 5–12 13–24 .24
Mean monthly total cost (US> >$)— 377 (337–418) 183 (160–206) 161 (138–183) 115 (98–131)
Baseline CD4 count (cells/ml) ,50 1.98 (1.74–2.22) 1.35 (1.07–1.63) 1.28 (1.05–1.51) 1.23 (0.97–1.48)
50–199 1.34 (1.20–1.48) 1.08 (0.94–1.21) 1.02 (0.87–1.17) 1.31 (1.11–1.51)
200–349 1 (referent) — — —
$350 1.57 (1.21–1.92) 1.39 (0.97–1.8) 1.43 (0.96–1.89) 1.12 (0.78–1.45)
Baseline viral load (copies/ml) $100,000 1.24 (1.10–1.37) 1.08 (0.93–1.23) 1.08 (0.94–1.23) 1.09 (0.95–1.23)
,100,000 1 (referent) — — —
Age at starting ART (y) ,25 1.03 (0.81–1.26) 0.82 (0.64–0.99) 0.83 (0.60–1.06) 0.85 (0.59–1.12)
25–49 1 (referent) — — —
$50 1.20 (0.97–1.43) 1.14 (0.87–1.42) 1.01 (0.79–1.23) 1.52 (0.72–2.32)
Sex Male 0.98 (0.87–1.10) 1.00 (0.83–1.17) 0.91 (0.77–1.06) 0.91 (0.75–1.06)
Female 1 (referent) — — —
NNRTI Nevirapine 0.87 (0.77–0.96) 0.89 (0.78–1.00) 1.11 (0.96–1.27) 1.02 (0.86–1.18)
Efavirenz 1 (referent) — — —
NRTI combination D4T/3TC 1.05 (0.88–1.22) 1.01 (0.80–1.22) 0.95 (0.74–1.16) 0.96 (0.61–1.32)
Other 0.91 (0.81–1.02) 0.98 (0.82–1.14) 1.05 (0.88–1.22) 1.06 (0.84–1.27)
AZT/3TC 1 (referent) — — —
Duration CD4+ cell count monitoring $6m o 0.76 (0.67–0.85) 0.98 (0.84–1.12) 1.01 (0.87–1.16) 1.30 (1.06–1.54)
,6m o 1 (referent) — — —
Therapy Second line 1.65 (1.09–2.2) 3.10 (0.43–5.76) 1.94 (1.45–2.44) 2.06 (1.53–2.58)
First line 1 (referent) — — —
Mean overall ART adherence ,38% 0.84 (0.75–0.94) 1.00 (0.86–1.14) 1.17 (0.98–1.35) 1.54 (1.21–1.86)
38%–73% 1.08 (0.97–1.20) 1.25 (1.01–1.49) 1.12 (0.97–1.27) 1.28 (1.07–1.50)
74%–92% 0.85 (0.77–0.94) 1.25 (1.06–1.44) 1.06 (0.92–1.21) 1.09 (0.92–1.26)
.92% 1 (referent) — — —
A log-link function with a gamma distribution was used in the model. Numbers in parentheses are the 95% confidence intervals. 3TC, lamivudine; AZT, zidovudine; D4T,
stavudine.
doi:10.1371/journal.pmed.1000189.t002
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from our analysis. We found that the ART component of costs was
relatively small compared with other studies in resource-limited
settings [2,25,27], which could be related to higher hospitalisation
and other costs in our private sector setting. Younger age has been
found to be associated with increased costs in some [28,29], but
not all studies [2]. We found a significant age effect with younger
age (,25 y) associated with lower early but higher later costs and
older age ($50 y) associated with higher early and especially later
costs. Finally, unlike the finding of another South African study
[2], sex was not independently associated with costs, even after
controlling for pregnancy-related costs and the higher proportion
of men being on efavirenz. It is possible that our inclusion of ART
adherence in our multiple regression model adjusted for sex
differences, as we have previously shown that men have lower
ART adherence than women [30].
There are a number of limitations to this analysis. First, our
cohort consisted of private sector patients when the majority of
patients in resource-limited settings are treated in the public sector.
However, the baseline characteristics of our cohort (CD4+ cell
count, proportion of females, and age) are comparable with
cohorts from low-income countries [20,31]. The BMI was
,18.5 kg/m
2 in 13% of our cohort compared with 19% in a
South African public sector cohort [32], but their patients had
more advanced disease as evidenced by their lower baseline CD4+
cell counts. These baseline nutritional differences would likely
impact outcomes. We restricted our analysis to patients receiving
NNRTI-based first line ART regimens, in keeping with WHO
recommendations for resource-limited settings [8]. While we
would not claim that our actual cost findings are generalisable to
public sector settings or to other countries, we would argue that
the variables that drive early and late costs are likely to be relevant
even if the magnitude of the effect could differ.
Second, the impact of specific AIDS-defining illnesses on
outcomes and costs was not included in this analysis because
these data were not available. Third, as a provider’s perspective
was chosen for this analysis, the cost to society is not fully
represented because we did not have data on direct non-health
care costs and indirect costs. However, a provider’s perspective is
more appropriate for the aim of this study, which was to unpack
the key drivers of health care costs in order to inform appropriate
budgeting and planning. Fourth, the characteristics of the patients
who left the scheme were different from those who remained,
which may have affected our findings. However, there was no
significant difference in the key baseline characteristic of CD4+
cell count and many of the other differences (e.g., age, difference of
0.1 log10 viral load) were small and are of questionable
importance. Fifth, we chose to use the tariff amount as opposed
to the amount claimed or reimbursed so that similar services
would take the same monetary value and have further assumed
Figure 3. The proportional change in mean total monthly costs over time associated with baseline CD4 cell count. Baseline CD4 count
was compared with the referent group (200 cells/ml) within each time interval from 4 mo before starting ART to 60 mo on ART with lighter blue
indicating higher relative costs.
doi:10.1371/journal.pmed.1000189.g003
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this could be a shortcoming, it is common to assume that market
prices are a proxy for opportunity costs in economic evaluation
given the difficulties in evaluating the latter [33]. Finally, cost
minimisation should not be the only goal of health care providers,
and other important aspects of care such as quality and outcomes
are not addressed by our analysis.
In conclusion, we have described the temporal trends of costs of
a large private sector HIV disease management programme in
Southern Africa and shown that associations with costs change
over time. Interventions that should reduce early costs include
starting ART at higher CD4 counts and being in HIV care for
longer periods before starting ART. Our results also indicate that
systems to detect suboptimal ART adherence and interventions
that improve adherence would reduce later costs. The increasing
impact of ART adherence on costs over time suggests that this
variable should be incorporated in economic models of ART.
Supporting Information
Figure S1 Total monthly costs from 36 mo before starting ART
to 60 mo on ART. Median and interquartile range, mean, and
running-line least squares smooth are shown.
Found at: doi:10.1371/journal.pmed.1000189.s001 (0.15 MB
TIF)
Figure S2 The proportional change in mean total monthly costs
over time associated with baseline HIV viral load. Baseline HIV
viral load was compared with the referent group ($100,000 cop-
ies/ml) within each time interval from 4 mo before starting ART
to 60 mo on ART with lighter blue indicating higher relative costs.
Found at: doi:10.1371/journal.pmed.1000189.s002 (0.31 MB
TIF)
Figure S3 The proportional change in mean total monthly costs
compared over time associated with age at starting ART. Age at
ART was compared with the referent group (37 y) within each
time interval from 4 mo before starting ART to 60 mo on ART
with lighter blue indicating higher relative costs.
Found at: doi:10.1371/journal.pmed.1000189.s003 (0.40 MB
TIF)
Author Contributions
ICMJE criteria for authorship read and met: RL SC MH AD LR FL GM.
Agree with the manuscript’s results and conclusions: RL SC MH AD LR
FL GM. Designed the experiments/the study: RL GM. Analyzed the data:
RL MH AD FL. Collected data/did experiments for the study: MH. Wrote
the first draft of the paper: RL. Contributed to the writing of the paper: SC
MH AD LR FL GM. Ccontributed to the overall study design and
methodology: SC. Collection and preparation of data used in the study:
MH. Provided input into data analysis methodology: MH. Statistical
consultant to the revision of this paper: FL. Reviewed various drafts of the
paper: FL.
References
1. Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, et al. (2006) The
direct costs of HIV/AIDS care. Lancet Infect Dis 6: 171–177.
2. Harling G, Wood R (2007) The evolving cost of HIV in South Africa: changes in
health care cost with duration on antiretroviral therapy for public sector patients.
J Acquir Immune Defic Syndr 45: 438–354.
3. Department of Health (2003) Operational plan for comprehensive HIV and
AIDS care, management and treatment for South Africa. Available: www.info.
gov.za/otherdocs/2003/aidsoperationalplan.pdf. Accessed 1 April 2008.
4. Rosen S, Vincent JR, MacLeod W, Fox M, Thea DM, et al. (2004) The cost of
HIV/AIDS to businesses in southern Africa. AIDS 18: 317–324.
Figure 4. The proportional change in mean total monthly costs over time associated with overall ART adherence. Overall ART
adherence was compared with the referent group (75%) within each time interval from 4 mo before starting ART to 60 mo on ART with lighter blue
indicating higher relative costs.
doi:10.1371/journal.pmed.1000189.g004
Drivers of Antiretroviral Treatment Costs
PLoS Medicine | www.plosmedicine.org 9 December 2009 | Volume 6 | Issue 12 | e10001895. Regensberg L (1999) Aid for AIDS: an innovative solution. AIDS Anal Afr 9:
10–11.
6. (UNAIDS) JUNPoHA (2008) Report on the global AIDS epidemic. Geneva:
UNAIDS.
7. (2007) HIV & AIDS and STI strategic plan for South Africa. Pretoria: South
African National AIDS Council (SANAC). pp 1–136.
8. WHO (2006) Antiretroviral therapy for HIV infection in adults and adolescents
in resource-limited settings: towards universal access: recommendations for a
public health approach. Geneva: World Health Organisation.
9. Regensberg L, Hislop M (2003) Aid for AIDS–A report back on more than four
years of HIV/AIDS disease management in Southern Africa. South Afr J HIV
Med 2: 7–10.
10. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy
programs in resource-poor settings: a meta-analysis of the published literature.
Clin Infect Dis 41: 217–224.
11. Taverne B (2003) Free dispensing of antiretroviral treatments in Africa. Bull Soc
Pathol Exot 96: 241–244.
12. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, et al. (2008) Early loss
of HIV-infected patients on potent antiretroviral therapy programmes in lower-
income countries. Bull World Health Organ 86: 559–567.
13. Hellinger FJ, Fleishman JA (2000) Estimating the national cost of treating people
with HIV disease: patient, payer, and provider data. J Acquir Immune Defic
Syndr 24: 182–188.
14. Statistics South Africa (2009) Consumer Price Index excluding interest rates on
mortgage bonds (CPIX). Available: http://www.statssa.gov.za/keyindicators/
cpix.asp. Accessed 1 May 2008.
15. OANDA.COM: The Currency Site. Available: http://www.oanda.com.
Accessed 10 January 2008.
16. Thompson SG, Barber JA (2000) How should cost data in pragmatic
randomised trials be analysed? BMJ 320: 1197–1200.
17. Dodd S, Bassi A, Bodger K, Williamson P (2006) A comparison of multivariable
regression models to analyse cost data. J Eval Clin Pract 12: 76–86.
18. Microsoft Corporation (2003) Microsoft Access. Redmond (Washington):
Microsoft Corporation.
19. StataCorp (2007) Stata Statistical Software: Release 10. College Station
(Pennsylvania): StataCorp LP.
20. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006)
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:
comparison between low-income and high-income countries. Lancet 367:
817–824.
21. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007)
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy
and virologic outcomes. Ann Intern Med 146: 564–573.
22. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to
highly active antiretroviral therapy assessed by pharmacy claims predicts survival
in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78–84.
23. Gross R, Bilker WB, Wang H, Chapman J (2008) How long is the window of
opportunity between adherence failure and virologic failure on efavirenz-based
HAART? HIV Clin Trials 9: 202–206.
24. Harling G, Orrell C, Wood R (2007) Healthcare utilization of patients accessing
an African national treatment program. BMC Health Serv Res 7: 80.
25. Rosen S, Long L, Sanne I (2008) The outcomes and outpatient costs of different
models of antiretroviral treatment delivery in South Africa. Trop Med Int
Health 13: 1005–1015.
26. Cleary SM, McIntyre D, Boulle AM (2006) The cost-effectiveness of
Antiretroviral Treatment in Khayelitsha, South Africa - a primary data analysis.
Cost Eff Resour Alloc 4: 20.
27. Rosen S, Long L (2006) How much does it cost to provide antiretroviral therapy
for HIV/AIDS in Africa? Boston: Center for International Health and
Development, Boston University School of Public Health. pp 1–11.
28. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, et al. (2001)
Expenditures for the care of HIV-infected patients in the era of highly active
antiretroviral therapy. N Engl J Med 344: 817–823.
29. Aracena B, Gutierrez JP, Bertozzi SM, Gertler P (2005) Cost of AIDS care in
Mexico: what are its main individual predictors? Arch Med Res 36: 560–566.
30. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, et al. (2004)
Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South
Africa. AIDS Res Hum Retroviruses 20: 1053–1056.
31. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, et al. (2008)
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient
characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia
and Latin America. Trop Med Int Health 13: 870–879.
32. Westreich D, MacPhail P, Van Riea A, Malope-Kgokongb B, Ive P, et al. (2009)
Effect of pulmonary tuberculosis on mortality inpatients receiving HAART.
AIDS 23: 707–715.
33. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005)
Methods for the economic evaluation of health care programmes. Oxford:
Oxford University Press.
Drivers of Antiretroviral Treatment Costs
PLoS Medicine | www.plosmedicine.org 10 December 2009 | Volume 6 | Issue 12 | e1000189Editors’ Summary
Background. About 30 million people (22 million people in
sub-Saharan Africa alone) are infected with the human
immunodeficiency virus (HIV), the cause of acquired
immunodeficiency syndrome (AIDS). HIV destroys immune
system cells (including CD4 cells, a type of lymphocyte),
leaving infected individuals susceptible to other infections.
Early in the AIDS epidemic, on average HIV-positive people
died within 10 years of infection. Then, in 1996, highly active
antiretroviral therapy (ART; combinations of powerful
antiretroviral drugs) was developed. For people living in
affluent, developed countries HIV/AIDS became a chronic,
treatable condition, but for the millions of HIV-infected
people living in low- and middle-income countries, effective
treatment was unavailable and HIV/AIDS remained a fatal
illness. In 2003, this situation was declared a global health
emergency and governments, international agencies, and
funding bodies began to implement plans to increase ART
coverage in developing countries. By the end of 2008, of the
9.5 million people in need of ART in low- and middle-income
countries, more than 4 million people were receiving
treatment.
Why Was This Study Done? Good progress is being made
towards achieving universal access to ART, partly because
the cost of antiretroviral drugs has plummeted in developing
countries. But the provision of antiretroviral drugs is not the
only direct cost associated with ART. General practitioner,
specialist, and maternity-related care for patients receiving
ART, hospital accommodation when necessary, and the
investigations that are needed to monitor the progress of
HIV infection such as CD4 cell counts and viral load
measurements all incur considerable costs. To use their
limited resources effectively, public-health officials in
developing countries need to know as much as possible
about the direct costs of HIV health care but few studies
have investigated these costs, particularly those incurred
before an individual starts taking ART. In this study, the
researchers explore health care costs in a South African
private-sector HIV/AIDS program and examine the variables
that drive the costs of HIV health care around the time of
ART initiation and during later phases of ART.
What Did the Researchers Do and Find? The researchers
analyzed the direct costs of treating more than 100,000 HIV-
infected adults enrolled in a private HIV care program in
South Africa from 3 years before they started ART until up to
5 years after ART initiation; within this program, individuals
began to receive ART when their CD4 cell count fell below
350 cells/ml of blood. The researchers found a peak in direct
health costs from 4 months before to 4 months after starting
ART (the ‘‘peri-ART’’ period), which was driven mainly by
hospital costs. After the peri-ART period, costs dropped
(although not to the levels seen before this period) and
stabilized at an intermediate level for the next 5 years.
Detailed statistical analyses suggest that the key variables
associated with higher costs in the peri-ART period were a
low baseline CD4 cell count, a high baseline HIV viral load,
and a shorter time in HIV care before ART initiation. The key
variable associated with higher costs later in ART was lower
adherence to the drug therapy. That is, costs were higher
among patients who did not take their antiretroviral drugs
regularly.
What Do These Findings Mean? This study involved
patients enrolled in a private health care program in which
the criteria for initiating ART differed somewhat from those
recommended by the World Health Organization for ART
initiation in resource-limited settings. Thus, the absolute
mean total costs calculated by the researchers are unlikely to
be generalizable to public HIV care systems in South Africa
and in other resource-poor settings. However, the finding
that the drivers of mean total costs change considerably over
time may be generalizable and provides some useful
information for public-health planners that can now be
tested in other, more resource-limited patient populations. In
particular, the findings of this study suggest that the high
early costs of ART programs could be reduced by starting
ART at higher CD4 cell counts or by providing longer pre-
ART care. In addition, the findings suggest that monitoring
ART adherence and introducing interventions to improve
ART adherence could reduce the later direct costs of ART
programs.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000189.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on the HIV and AIDS in Africa, and on universal access
to AIDS treatment (in English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment, including the Septem-
ber 2009 progress report (in English and French)
N The US Centers for Disease Control and Prevention also
provides information on global efforts to deal with the
HIV/AIDS epidemic
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